MDM2-SNP 309 allele status does not affect sensitivity to MDM2 inhibitors in CLL

Blood

Volumn 112, Issue 5, 2008, Pages 2169-

  Malek, Sami N ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ALLELE; CHRONIC LYMPHATIC LEUKEMIA; DRUG SENSITIVITY; HUMAN; LETTER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650760161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-165126     Document Type: Letter

References (2)

1. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008; 26:2252-2257.
2. Saddler C, Ouillette P. Kujawski L. et al. Comprehensive biomarker and genomic analysis identities p53 status as the major determinant ot response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008;111:1584-1593.